Kalaris Therapeutics

KLRS · NASDAQ

$2.07+$0.16 (+8.38%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.91

About KLRS

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. The company is headquartered in Berkeley Heights, New Jersey and currently employs 20 full-time employees. The company went IPO on 2020-07-30. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).

Employees: 20
Headquarters: Berkeley Heights, New Jersey
Listed: Jul 30, 2020
Sector: Health Care
Industry: Biotechnology
Website: kalaristx.com

Leadership

Kalaris Therapeutics executives
Name	Title	Since	Age
David Hallal	—	2018	59
Andrew Oxtoby	—	2025	51
Matthew Gall	—	—	49
Brett Hagen	—	—	52
Matthew Feinsod	—	—	54
Anthony Adamis	—	—	66
Srinivas Akkaraju	—	—	56
Michael Dybbs	—	—	50
Napoleone Ferrara	—	—	68
Morana Jovan-Embiricos	—	—	58
Leone Patterson	—	—	62

Similar companies

Companies in the same industry as Kalaris Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.